登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06888648,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Pancreatic ductal adenocarcinoma (PDAC) diagnosed by pathology (histology or cytology);
入选标准第 13 条
Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age included premenopause and women within 2 years after menopause;
入选标准第 9 条
Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age include premenopause and women within 2 years after menopause;
入选标准第 17 条
An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;
入选标准第 5 条
An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;
入选标准第 15 条
According to the efficacy evaluation criteria for solid tumors (RECIST 1.1);
入选标准第 6 条
At the same time with other malignant tumors, but cured basal cell cancer, thyroid cancer, cervical dysplasia, etc., have been in the disease for more than 5 years or do not considered to be easy to relapse except;
排除标准第 2 条
Patients with positive human immunodeficiency virus (HIV) antibody, positive treponema pallidum for syphilis (TP) antibody, active hepatitis C (positive hepatitis C virus (HCV) antibody and positive HCV RNA result), active hepatitis B;
排除标准第 6 条
Women born during pregnancy or lactation;
排除标准第 11 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06888648,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntary signing of the informed consent form; Age: 18 and 75 years old, male or female; Evaluation as metastatic pancreatic cancer or postoperative recurrence according to the 2024 NCCN guidelines; No systemic treatment, or disease progression with gemcitabine-based first-line chemotherapy. An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1; According to the efficacy evaluation criteria for solid tumors (RECIST 1.1); Can obtain sufficient fresh tumor tissue samples for exome and transcriptome sequencing analysis; Main organ function of heart, liver and kidney is normal: Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age included premenopause and women within 2 years after menopause; Ability to follow the study protocol and follow-up procedures. Voluntary signing of the informed consent form; Age: 18 and 75 years old, male or female; Pancreatic ductal adenocarcinoma (PDAC) diagnosed by pathology (histology or cytology); No systemic treatment or gemcitabine-based first-line chemotherapy. An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1; Main organ function of heart, liver and kidney is normal: Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age include premenopause and women within 2 years after menopause; Ability to follow the study protocol and follow-up procedures.排除标准:Exclusion Criteria:
Pancreatic cancer has central nervous system metastasis or meningeal metastasis; At the same time with other malignant tumors, but cured basal cell cancer, thyroid cancer, cervical dysplasia, etc., have been in the disease for more than 5 years or do not considered to be easy to relapse except; History of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation; Patients with immunosuppressants, that is, those who require regular use of immunosuppressants 4 weeks before the screening period and the clinical study, including but not limited to the following conditions: severe asthma, autoimmune diseases or immune deficiency, treated with immunosuppressive drugs, and known history of primary immunodeficiency; except type 1 diabetes, autoimmune-related hypothyroidism requiring hormone therapy, vitiligo and psoriasis that do not require systemic therapy; Active bacterial or fungal infection identified by clinical diagnosis; a history of active TB or tuberculosis; Patients with positive human immunodeficiency virus (HIV) antibody, positive treponema pallidum for syphilis (TP) antibody, active hepatitis C (positive hepatitis C virus (HCV) antibody and positive HCV RNA result), active hepatitis B; Herpesvirus infection (except those who scab for more than 4 weeks); respiratory virus infection (except those who have recovered for more than 4 weeks); Uncontrolled complications include but are not limited to active infection, symptomatic congestive heart failure, unstable angina, arrhythmia; severe coronary artery disease or cerebrovascular disease, or other diseases considered unacceptable by the investigator; Previous history of drug abuse, clinical or psychological or social factors affecting informed consent or study implementation; a history of mental illness; Patients with a history of food, drug or vaccine allergy or other potential immunotherapy allergies as considered by the Investigator. Women born during pregnancy or lactation; The investigator is not fit for enrollment or may not complete the trial for other reasons.
引自 ClinicalTrials.gov, NCT06888648, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06888648,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。